Table of Contents
ISRN Neurology
Volume 2012, Article ID 642345, 10 pages
http://dx.doi.org/10.5402/2012/642345
Review Article

Glioblastoma Multiforme: Novel Therapeutic Approaches

1Instituto de Biotecnologia e Bioengenharia (IBB) and Departamento de Bioengenharia, Instituto Superior Técnico, 1049-001 Lisbon, Portugal
2Amrita Therapeutics Ltd., S. G. Highway, Thaltej, Ahmedabad 380 054, India
3Laboratory of Immunology, Centre for DNA Fingerprinting and Diagnostics, Nampally, Hyderabad 500 001, India
4Department of Microbiology and Immunology, University of Illinois College of Medicine, 835 South Wolcott Avenue, Chicago, IL 60612, USA

Received 29 August 2011; Accepted 20 October 2011

Academic Editor: R. Yamanaka

Copyright © 2012 Arsenio M. Fialho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. M. Pardridge, “Blood-brain barrier delivery,” Drug Discovery Today, vol. 12, no. 1-2, pp. 54–61, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. J. Begley, “ABC transporters and the blood-brain barrier,” Current Pharmaceutical Design, vol. 10, no. 12, pp. 1295–1312, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. W. J. Marks, J. L. Ostrem, L. Verhagen et al., “Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial,” The Lancet Neurology, vol. 7, no. 5, pp. 400–408, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. D. Fortin, C. Gendron, M. Boudrias, and M. P. Garant, “Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis,” Cancer, vol. 109, no. 4, pp. 751–760, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. Y. Zhang and W. M. Pardridge, “Delivery of β-galactosidase to mouse brain via the blood-brain barrier transferrin receptor,” Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 3, pp. 1075–1081, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. Yamamoto, K. Ikeda, K. Ohshima, H. Tsugu, H. Kimura, and M. Tomonaga, “Increased expression of low density lipoprotein receptor-related protein/α2-macroglobulin receptor in human malignant astrocytomas,” Cancer Research, vol. 57, no. 13, pp. 2799–2805, 1997. View at Google Scholar · View at Scopus
  7. B. J. Spencer and I. M. Verma, “Targeted delivery of proteins across the blood-brain barrier,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7594–7599, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. I. M. Germano and E. Binello, “Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside,” Journal of Neuro-Oncology, vol. 93, no. 1, pp. 79–87, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. Demeule, J. C. Currie, Y. Bertrand et al., “Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2,” Journal of Neurochemistry, vol. 106, no. 4, pp. 1534–1544, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Regina, M. Demeule, C. Chi et al., “Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2,” British Journal of Pharmacology, vol. 155, no. 2, pp. 185–197, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. R. Gabathuler, “Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases,” Neurobiology of Disease, vol. 37, no. 1, pp. 48–57, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. L. Liu, K. Guo, J. Lu et al., “Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier,” Biomaterials, vol. 29, no. 10, pp. 1509–1517, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. Clarke, N. Butowski, and S. Chang, “Recent advances in therapy for glioblastoma,” Archives of Neurology, vol. 67, no. 3, pp. 279–283, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. D. Prados, S. M. Chang, N. Butowski et al., “Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma,” Journal of Clinical Oncology, vol. 27, no. 4, pp. 579–584, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. S. Chi, A. D. Norden, and P. Y. Wen, “Antiangiogenic strategies for treatment of malignant gliomas,” Neurotherapeutics, vol. 6, no. 3, pp. 513–526, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. T. T. Huang, S. M. Sarkaria, T. F. Cloughesy, and P. S. Mischel, “Targeted therapy for malignant glioma patients: lessons learned and the road ahead,” Neurotherapeutics, vol. 6, no. 3, pp. 500–512, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. R.-Y. Bai, V. Staedtke, and G. J. Riggins, “Molecular targeting of glioblastoma: drug discovery and therapies,” Trends in Molecular Medicine, vol. 17, no. 6, pp. 301–312, 2011. View at Publisher · View at Google Scholar · View at PubMed
  18. S. H. Huang and A. Y. Jong, “Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier,” Cellular Microbiology, vol. 3, no. 5, pp. 277–287, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. K. S. Doran, E. J. Engelson, A. Khosravi et al., “Blood-brain barrier invasion by group B Streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid,” The Journal of Clinical Investigation, vol. 115, no. 9, pp. 2499–2507, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. Coureuil, G. Mikaty, F. Miller et al., “Meningococcal type IV pili recruit the polarity complex to cross the brain endothelium,” Science, vol. 325, no. 5936, pp. 83–87, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. O. Join-Lambert, P. C. Morand, E. Carbonnelle et al., “Mechanisms of meningeal invasion by a bacterial extracellular pathogen, the example of Neisseria meningitides,” Progress in Neurobiology, vol. 91, no. 2, pp. 130–139, 2010. View at Google Scholar
  22. A. M. Fialho, F. J. Stevens, T. K. Das Gupta, and A. M. Chakrabarty, “Beyond host-pathogen interactions: microbial defense strategy in the host environment,” Current Opinion in Biotechnology, vol. 18, no. 3, pp. 279–286, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. A. M. Fialho and A. M. Chakrabarty, “Promiscuous anticancer drugs from pathogenic bacteria: rational versus intelligent drug design,” in Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools, A. M. Fialho and A. M. Chakrabarty, Eds., pp. 181–198, John Wiley & Sons, Hoboken, NJ, USA, 2010. View at Google Scholar
  24. F. De Rienzo, R. R. Gabdoulline, M. C. Menziani, and R. C. Wade, “Blue copper proteins: a comparative analysis of their molecular interaction properties,” Protein Science, vol. 9, no. 8, pp. 1439–1454, 2000. View at Google Scholar · View at Scopus
  25. L. J. Jeuken, M. Ubbink, J. H. Bitter, P. van Vliet, W. Meyer-Klaucke, and G. W. Canters, “The structural role of the copper-coordinating and surface-exposed histidine residue in the blue copper protein azurin,” Journal of Molecular Biology, vol. 299, no. 3, pp. 737–755, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. D. Szklarczyk, A. Franceschini, M. Kuhn et al., “The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored,” Nucleic Acids Research, vol. 39, pp. D561–568, 2011. View at Google Scholar
  27. E. C. Gotschlich, M. S. Blake, and J. M. Koomey, “Cloning of the structural genes of three H8 antigens and of protein III of Neisseria gonorrhoeae,” Journal of Experimental Medicine, vol. 164, no. 3, pp. 868–881, 1986. View at Google Scholar
  28. C. S. Hong, T. Yamada, W. Hashimoto, A. M. Fialho, T. K. Das Gupta, and A. M. Chakrabarty, “Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein,” Cell Cycle, vol. 5, no. 15, pp. 1633–1641, 2006. View at Google Scholar
  29. D. G. Higgins and P. M. Sharp, “CLUSTAL: a package for performing multiple sequence alignment on a microcomputer,” Gene, vol. 73, no. 1, pp. 237–244, 1988. View at Google Scholar
  30. N. Saitou and M. Nei, “The neighbor-joining method: a new method for reconstructing phylogenetic trees,” Molecular Biology and Evolution, vol. 4, no. 4, pp. 406–425, 1987. View at Google Scholar
  31. B. N. Taylor, R. R. Mehta, T. Yamada et al., “Noncationic peptides obtained from azurin preferentially enter cancer cells,” Cancer Research, vol. 69, no. 2, pp. 537–546, 2009. View at Publisher · View at Google Scholar · View at PubMed
  32. J. M. Richards, M. A. Warso, D. Mehta et al., “A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors,” Journal of Clinical Oncology, vol. 29, 2011, abstract 2511. View at Google Scholar
  33. A. Chaudhari, M. Mahfouz, A. M. Fialho et al., “Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth,” Biochemistry, vol. 46, no. 7, pp. 1799–1810, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. C. S. Hong, T. Yamada, A. M. Fialho, T. K. Das Gupta, and A. M. Chakrabarty, “Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof,” US Patent No. 7,807,183, 2010.
  35. T. K. Das Gupta and A. M. Chakrabarty, “Compositions and methods to prevent cancer with cupredoxins,” US Patent No. 7,618,939, 2009.